Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2021
Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT StudyMartin Pfohl, Jochen Seufert, Anja Borck, et al.Journal of Medical Economics|July 21, 2012
Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in GermanyMartin Pfohl, Peter K Schädlich, Franz-Werner Dippel, et al.Diabetes, Obesity & Metabolism|September 13, 2021
Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safetyJochen Seufert, Peter Wiesli, Andreas Fritsche, et al.Innere Medizin (Heidelberg, Germany)|March 5, 2026
[Preventive fields in endocrinology/diabetology-The big five]Martin Pfohl, Martin Reincke, Jochen Seufert, et al.Diabetes, Obesity & Metabolism|January 20, 2026
Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo-Neo T2DM studyStefan Pscherer, Andreas Fritsche, Helmut Anderten, et al.Journal of Medical Economics|May 20, 2009
Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP studyOliver Schöffski, Lusine Breitscheidel, Ursula Benter, et al.Diabetes, Obesity & Metabolism|January 7, 2020
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world settingMartin Pfohl, François R Jornayvaz, Andreas Fritsche, et al.Diabetes, Obesity & Metabolism|May 10, 2019
Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and OPtimisation (TOP) registryMartin Pfohl, Stefan Pscherer, Andreas Fritsche, et al.Diabetes, Obesity & Metabolism|September 19, 2018
Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugsJochen Seufert, Andreas Fritsche, Stefan Pscherer, et al.Diabetes & Metabolic Syndrome|September 1, 2016
Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patientsThorsten Siegmund, Martin Pfohl, Thomas Forst, et al.Pageof 3